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Delayed graft function (DGF) in kidney transplantation is
associated with an increased risk of acute rejection. Myeloid
dendritic cells (DCs) are involved in graft rejection, whereas
plasmacytoid DCs may play a role in inducing tolerance.
We evaluated the presence and phenotype of the DCs in
renal graft biopsies of 15 patients with DGF collected
before and 7–15 days after transplantation. Biopsies taken
from normal patients and from transplant recipients with
acute calcineurin inhibitors (CNIs) nephrotoxicity served as
a control group. Specific markers of myeloid, plasmacytoid,
and mature DCs were imaged by confocal microscopy and
immunohistochemistry. In normal kidneys and pre-transplant
biopsies, sparse niches of myeloid and plasmacytoid cells
were found but these were significantly increased with few
mature cells during DGF. This same pattern was seen in acute
rejection but with overall higher cell numbers. In CNI
nephrotoxicity, myeloid cells were slightly increased but
plasmacytoid cells were significantly higher than in DGF.
Using a pig model, we found that a short period of warm
ischemia followed by reperfusion led to myeloid cell
infiltration of the kidney. Our data suggest that
ischemia-reperfusion injury may cause an imbalance
between intragraft myeloid and plasmacytoid DCs, which
might be related to DGF and acute rejection.
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Delayed graft function (DGF) is a form of acute renal failure
causing a prolonged hospitalization and a significant increase
in early transplant-related morbidity.1,2 In addition, DGF has
been associated with an increased risk of acute rejection, thus
influencing the survival of the graft in the short as well as in
the long term.1 The incidence of this condition varies from 2
to 50% of renal transplant world-wide and is strictly
dependent upon the features of the transplanted organ and
the length of cold ischemia time.1 Experimental studies
clearly show that both ischemia and the subsequent
reinstitution of regular blood flow in ischemically damaged
kidneys after hypothermic preservation activate a complex
sequence of events that sustain renal injury and play a pivotal
part in the development of DGF.3–5 Ischemia-reperfusion
injury is characterized by a significant activation of the innate
immunity resulting in the priming of the complement and
coagulation cascades within the graft and the subsequent
development of an extensive infiltration of inflammatory
cells, including neutrophils, monocytes, lymphocytes, and
dendritic cells (DCs).3–7
DCs are antigen-presenting cells that can promote and
regulate T, B and natural killer lymphocyte activity against
foreign and aberrant antigens.8 In addition, DCs are thought
to maintain tolerance to self, modulating the differentiation
of regulatory T cells (Treg).9–11 DCs originate from bone
marrow progenitors and travel through the systemic circula-
tion to non-lymphoid tissues, where they reside as immature
DCs.8,12 Immature DCs are characterized by a high capacity
for phagocytosis and antigen processing. Antigen uptake in
combination with an appropriate inflammatory stimulus
causes DCs to ‘mature’, switching their phenotype into an
immunostimulatory state.8,12 This maturation/activation
process is characterized by the loss of DCs ability to capture
antigens and an increased expression of distinct chemokine
receptors, major histocompatibility complex class II and
different adhesion and costimulatory molecules.8 These
changes enables DCs to move towards secondary lymphoid
tissues where they can present the foreign antigens to B and T
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cells, thus creating a bridge between the innate and adaptive
branches of the immune response.12,13
DCs are a heterogeneous group of cells. They are
comprised of multiple cell subsets that display different
functions and tissue localization. Two major subsets of
human circulating DC have been defined in the literature.14
CD11cþ /CD123dim/BDCA-2 DC, classically defined as
myeloid DC, can phagocytise antigens via their Fc receptors.
They are potent stimulators of Th1-polarized T-cell responses
and thus, in the transplantation setting, represent a major
player in the induction of acute graft rejection.14–16 In
contrast, CD11c/CD123hi/BDCA-2þ plasmacytoid DC that
fail to express Fc receptors exhibits poor phagocytic
potential. Thus, are notably weaker stimulators of allogenic
mixed lymphocyte responses and have been suggested to
modulate allogeneic T-cell hyporesponsiveness.17 Recently,
Ochando et al.18 demonstrated that plasmacytoid DCs are
essential for tolerance induction to vascularized cardiac
allografts. They reported that these cells acquire alloantigen
in the allograft and then move through the blood to home to
peripheral lymph nodes. In the lymph node, alloantigen-
presenting plasmacytoid DCs induce the generation of
Foxp3þ Treg. Depletion of plasmacytoid DCs or prevention
of their lymph node homing inhibits peripheral Treg cell
development and tolerance induction, whereas adoptive
transfer of plasmacytoid DCs induced Treg cell development
and prolonged graft survival. BDCA-2 and BDCA-4 are
surface markers, which specifically characterize plasmacytoid
DCs,19,20 whereas BDCA-1 and BDCA-3 define two different
sub-populations of myeloid DCs.19,21
The aim of this study was to characterize the phenotype of
graft-infiltrating DCs before and after transplantation in
patients with DGF and no histological evidence of acute
rejection and to assess the role of ischemia-reperfusion injury
in this phenomenon.
RESULTS
BDCA-1 antigen expression in normal, pre and post-trans-
plant kidneys
Among the myeloid DCs subsets, two different sub-popula-
tions were identified as BDCA1þ cells and BDCA3þ cells,
respectively.19,21 Indirect immunofluorescence and confocal
microscopy analysis showed that only few BDCA-1-stained
cells were detected within the interstitial area in the biopsies
obtained from normal kidneys and cadaveric donor kidneys
before transplantation (Figure 1a and b, respectively). On the
contrary, a high number of infiltrating BDCA-1þ DCs was
observed in the interstitial area of kidneys with DGF (Figure
1c). To demonstrate that this event was not due to either
transplantation per se or acute tubular necrosis, we evaluated
the presence of DCs also in post-transplant renal biopsies of
patients with acute tubular necrosis due to acute calcineurin
inhibitor (CNI) nephrotoxicity in the first 6 months after
transplantation. A diffuse interstitial cell staining for BDCA-1
was observed also in this group of biopsies, although not at
the same extent of DGF biopsies (Figure 1d).
The quantification of BDCA-1 expression level, indeed,
demonstrated a statistically significant increase in the
number of BDCA-1þ cells in DGF and in CNI nephrotoxi-
city biopsies, as compared with normal kidneys and pre-
transplant biopsies (Figure 1e). Figure 1f illustrates by
immunohistochemistry the localization of myeloid DC in
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Figure 1 | Characterization of BDCA-1þ myeloid DC in normal
and graft kidneys. Frozen human kidney sections were examined
for expression of BDCA-1 antigen (green staining) by single
immunofluorescence and confocal laser microscopy analysis in:
(a) normal kidney (n¼ 6); (b) Pre-transplant cadaveric donor kidney
(n¼ 21); (c) graft kidney with DGF (n¼ 15); (d) graft kidney with acute
CNI nephrotoxicity (CNI NTX) (n¼ 6). Nuclei were stained with
TO-PRO-3 (blue). Original higher magnification  630. (a, b) Both in
the normal human kidney and in the pre-transplant cadaveric kidney
few BDCA-1þ cells were observed. (c) The graft kidney with DGF
contained numerous tubulointerstitial cells expressing the DC marker
BDCA-1. (d) A lower number of interstitial BDCA1þ cells was
observed in the transplant recipients with acute tubular necrosis due
to CNI nephrotoxicity. (e) Quantitative analysis of BDCA-1þ cells, in
normal kidney, in cadaveric human kidney before transplant and in
graft kidneys. Results are expressed as the mean7s.d. of BDCA-1þ
cells. *Po0.0001 versus normal kidney and pre-transplant biopsies.
**Po0.05 versus DGF. (f) Immunohistochemistry for BDCA-1þ DCs in
cryosections of DGF renal tissue. Immunoperoxidase staining was
carried out as described in the Patients and methods section. Specific
staining was detected by DAB (brown) and nuclei were
counterstained by haematoxylin (blue). BDCA-1þ DCs are located in
the interstitial and peri-glomerular area of renal cortical region.
Original magnification  200. Arrows indicate BDCA-1þcells.
Kidney International (2007) 72, 994–1003 995
A Loverre et al.: Dendritic cells and delayed graft function o r i g i n a l a r t i c l e
DGF biopsies. BDCA-1þ cells were mainly located within the
interstitial and peri-glomerular area.
BDCA-3 antigen expression in normal, pre- and post-
transplant kidneys
To confirm the presence of infiltrating immature myeloid DC
in the renal graft with DGF, we investigated the expression of
another cell surface marker for this DC subset: BDCA-3. We
observed a pattern of BDCA-3 staining resembling the one
observed for BDCA-1 (Figure 2). Only few cells expressing
BDCA-3 were detected in the tubulointerstitial area in
normal renal tissue and in the biopsies of cadaveric donor
kidneys (Figure 2a and b, respectively), whereas the number
of infiltrating BDCA-3þ cells was clearly increased in the
biopsies performed 7–15 days after transplantation in the
patients with DGF (Figure 2c). The same pattern of BDCA-3
expression (Figure 1d) was found also in the group of post-
transplant kidneys with CNI nephrotoxicity (Figure 2d). The
quantification of BDCA-3-positive cells demonstrated a
statistically significant difference between graft kidneys with
DGF and normal kidneys, pre-transplant biopsies, and post-
transplant graft biopsies of patients with CNI nephrotoxicity
(Figure 2e). Immunohistochemistry for BDCA-3 confirmed
the prevalent interstitial distribution of BDCA-3þ myeloid
DCs (Figure 2f).
BDCA-4 antigen expression in normal, pre-, and post-
transplant kidneys
We then investigated the expression of BDCA-4, a novel
antigens that is highly restricted to plasmacytoid DCs in both
blood and peripheral tissues. Immunofluorescence analysis of
this human plasmacytoid DC antigen on frozen tissue of
donor and graft recipients showed that BDCA-4þ cells
infiltrating the tubulointerstitial area, hardly detectable in
normal and pre-transplant kidneys (Figure 3a and b,
respectively), were increased in post-transplant biopsies
(Figure 3c–d).
Quantification of BDCA-4þ cells demonstrated that the
difference observed between pre- and post-transplant biop-
sies was statistically significant (Figure 3e). Interestingly,
BDCA-4þ cell number in biopsies of CNI nephrotoxicity was
markedly higher then in patients with DGF (Figure 3e).
Immunohistological analysis of BDCA-4þ DCs confirmed
the interstitial distribution of this DC population (Figure 3f).
Histograms in Figure 4 show that the ratio BDCA-1þ /
BDCA-4þ cells and BDCA-3þ /BDCA-4þ cells (myeloid/
plasmacytoid DCs) were significantly increased in DGF
biopsies when compared with normal, pre-, and post-
transplant kidneys with CNI nephrotoxicity.
DC-LAMP antigen expression in normal, pre-, and post-
transplant kidneys
Finally, we sought to determine whether infiltrating DCs
presented any feature of maturation. To this purpose, we
investigated the expression of DC-lysosome-associated
membrane protein (LAMP), a highly specific marker of
human DC maturation expressed in the lysosomal major
histocompatibility complex class II compartment.22 Indirect
immunofluorescence and confocal microscopy analysis
showed that DC-LAMPþ cells were absent in normal
conditions in donor pre-transplant kidneys and in post-
transplant graft biopsies (Figure 5a, b and d, respectively).
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Figure 2 | Characterization of BDCA-3þ myeloid DC in the normal
and graft kidneys. Frozen human kidney sections were examined for
expression of BDCA-3 antigen (green) by single immunofluorescence
and confocal analysis in: (a) normal kidney (n¼ 6); (b) pre-transplant
cadaveric donor kidney (n¼ 21); (c) graft kidney with DGF (n¼ 15);
(d) graft kidney with acute CNI nephrotoxicity (CNI NTX) (n¼ 6).
Nuclei were stained with TO-PRO-3 (blue). Original higher
magnification  630. (a–b) Note that BDCA-3 expression was minimal
in the tubulo-interstitial area, both in the normal kidney and in the
pre-transplant cadaveric kidney. (c) In the graft recipients with DGF,
we observed a significantly increased number of BDCA-3þ cells in
the same area. (d) Also acute CNI nephrotoxicity presented an
increased BDCA-3 expression, although to a lower extent of patients
with DGF. (e) Quantification of BDCA-3-stained cells in normal kidney,
in pre-transplant cadaveric donor kidney, DGF, and acute CNI NTX
biopsies. Results are expressed as the mean7s.d. of BDCA-3þ cells.
*Po0.0001 versus normal kidney and pre-transplant biopsies.
**Po0.05 versus DGF. (f) Immunohistologic distribution of BDCA-3þ
DCs in cryosections of DGF renal tissue. Immunoperoxidase staining
was carried out as described in the Patients and methods section.
Specific staining was detected by DAB (brown) and nuclei were
counterstained by haematoxylin (blue). BDCA-3þ as well as BDCA-1þ
myeloid DCs are located at tubulointerstitial level. Original
magnification  400. Arrows indicate BDCA-3þcells.
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DC-LAMPþ cells were scantly present within the interstitial
area in graft kidney of patients with DGF (Figure 5c) and
were mostly BDCA-1 positive (data not shown).
Also for DC-LAMP, however, the quantification of
positive cells demonstrated a statistically significant increase
in graft kidneys with DGF when compared with normal
kidneys, pre-transplant biopsies and post-transplant tissue
specimen from patients with CNI nephrotoxicity (Figure 5e).
BDCA antigens expression in acute allograft rejection
We, then, evaluated the presence and phenotype of DC in our
‘positive’ control group: biopsy samples from patients with
acute allograft rejection. As expected, we observed a dramatic
increase of both BDCA-1þ (Figure 6a, b and g) and BDCA-3þ
(Figure 6c, d and g) compared with normal kidneys. In both
cases, the number of cells/high power field was significantly
higher then in DGF biopsies. Also BDCA-4þ cells (Figure 6e,
f and g) were increased in the acute rejection samples,
although not at the same extent of myeloid DC.
BDCA antigens expression in native kidneys with acute
interstitial nephritis
We investigated the presence and the distribution of the
different DC subsets by immunohistochemistry in native
kidneys with acute interstitial nephritis as a further control
group. As shown in Figure 6, we observed a slight and focal
increase of BDCA-1þ and BDCA-3þ myeloid DCs within
the tubulointerstitial area (Figure 7b–d) compared with
normal kidneys (Figure 7a–c), whereas BDCA-4þ plasmacy-
toid DCs (Figure 7f) were hardly detectable. No expression of
DC-LAMPþ mature population was found in native kidneys
with acute interstitial nephritis (data not shown).
SWC3a antigen expression in the experimental model of
ischemia-reperfusion injury
To confirm that myeloid DC infiltration of the graft was
indeed due to ischemia-reperfusion and was not the result of
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Figure 3 | Characterization of BDCA-4þ plasmacytoid DC in
normal and graft kidneys. Frozen human kidney sections were
examined for expression of plasmacytoid DC antigen BDCA-4 (green)
by immunofluorescence and confocal analysis in: (a) normal kidney
(n¼ 6); (b) pre-transplant cadaveric donor kidney (n¼ 21); (c) graft
kidney with DGF (n¼ 15); (d) Graft kidney with acute CNI
nephrotoxicity (CNI NTX) (n¼ 6). Nuclei were stained with TO-PRO-3
(blue). Original magnification  630. (a, b) The image analysis
showed few BDCA-4-positive cells both in the normal kidney and in
the pre-transplant donor kidney. (c) In the graft recipients who had
DGF, we detected a modest increase of plasmacytoid DCs in all
interstitial area. (d) In the group of patients with acute tubular
necrosis due to CNI nephrotoxicity, we observed a significant
increase of BDCA-4þcells. (e) Quantification of BDCA-4-stained cells
in normal kidney, human kidney before transplant, and graft kidney.
Results are expressed as the mean7s.d. of BDCA-4þ cells. *Po0.05
versus normal kidney and pre-transplant biopsies. **Po0.0001 versus
normal kidney, pre-transplant biopsies and DGF. Arrows indicate
BDCA-4þcells. (f) Immunohistologic analysis of BDCA-4þ
plasmacytoid DCs in cryosections of DGF renal tissue. Staining was
detected by DAB (brown) and nuclei counterstained by haematoxylin
(blue). BDCA-4þ DCs are located in interstitial area of renal cortical
region. The magnification used is  400. Arrows indicate BDCA-4þ
cells.
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Figure 4 | Comparison of the myeloid/plasmacytoid DCs ratio
between patient groups. The ratio mDC/pDC significantly increased
in DGF biopsies when compared to normal and pre-transplant
kidneys. *Po0.05 versus normal kidney, pre-transplant biopsies, and
patients with acute CNI nephrotoxicity (CNI NTX).
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transplantation, we moved to an animal model of ischemia-
reperfusion injury. In this setting, we investigated the
expression of another cell surface marker for the identifica-
tion of swine myeloid DC, SWC3a.23–25 The analysis of the
swine renal tissue, carried out by immunofluorescence
and confocal laser microscopy, demonstrated only few
SWC3aþ cells in the interstitial area before ischemia
(Figure 8a). On the contrary, a high number of infiltrating
myeloid DCs was found within the interstitial area between
15 and 30 min after reperfusion (Figure 8b–d). The
quantification of SWC3a expression level demonstrated a
significant increase of the number of infiltrating myeloid DCs
after 15–30 min of reperfusion compared with basal condi-
tion (Figure 8e).
a
c
e
d
b
Normal
kidney
M
ea
n 
of
 D
C-
La
m
p+
 
ce
lls
3
2.5
2
1.5
1
0.5
0
Pre-tx DGF CNI NTX
Figure 5 | Characterization of DC-LAMPþ cells in graft kidneys.
Frozen human kidney sections were examined for expression of DC-
LAMP protein in mature DC (green) by confocal laser microscopy in:
(a) normal kidney (n¼ 6); (b) pre-transplant cadaveric donor kidney
(n¼ 21); (c) graft kidney with DGF (n¼ 15); (d) graft kidney with acute
CNI nephrotoxicity (CNI NTX) (n¼ 6). Original higher magnification
 630. (a, b) No DC-LAMP immunoreactivity was observed in the
normal and in pre-transplant cadaveric kidneys. (c) In human grafts
with DGF, only few DCs expressed DC-LAMP protein, a specific
marker for mature human DC. (d) In post-transplant kidney with
acute CNI nephrotoxicity, we could not detect any DC-LAMPþ cell.
(e) Quantification of DC-LAMP-stained cells in normal kidney, human
kidney before transplant and graft kidney. Results are expressed as
the mean7s.d. of DC-LAMPþ cells. *Po0.05 versus normal kidney,
pre-transplant biopsies, and acute CNI nephrotoxicity.
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Figure 6 | Analysis of BDCAþ DCs in acute allograft rejection.
Cryosections of normal (a, c e) (n¼ 6) and acute rejection (b, d, f)
(n¼ 6) renal tissue were examined for BDCA-1 (a, b), BDCA-3 (c, d)
and BDCA-4 (e, f) expression by immunofluorescence/confocal
microscopy as described in the Patients and methods section.
Staining was detected by DAB (brown) and nuclei counterstained by
haematoxylin (blue). Few BDCA-1þ and BDCA-3þ myeloid DCs were
found in normal kidney, whereas a slight and focal increase in the
number of these immature cell populations was observed in
interstitial nephritis biopsies. The BDCA-4þ DCs were hardly
detectable both in normal and in pathological tissue samples.
(g) Quantification of BDCA-1, BDCA-3, and BDCA-4 cells in normal
kidney and acute allograft rejection biopsies. Results are expressed
as the mean7s.d. *Po0.05 versus normal kidney.
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DISCUSSION
In this study, we demonstrated for the first time that the
histological picture of acute tubular necrosis underlying DGF
in renal transplantation is characterized by a diffuse
interstitial infiltration of immature myeloid DCs. We found
that the cortex of the transplanted kidneys contained a high
number of BDCA-1þ and BDCA-3þ DCs, mostly located
within the tubulointerstitial area. On the contrary, in normal
and pre-transplant kidney biopsies, we observed only sparse
niches of this cell population. In addition, using BDCA-4 as a
surface marker for plasmacytoid DC, we found that
immature plasmacytoid DCs, hardly detectable in normal
and pre-transplant kidneys, are only slightly increased in
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Figure 7 | Immunohistochemistry analysis of BDCAþ DCs in
native kidney with interstitial nephritis. Cryosections of normal
(a, c, e) (n¼ 6) and acute interstitial nephritis (b, d, f) (n¼ 4) renal
tissue were stained with immunoperoxidase for (a, b) BDCA-1,
(c, d) BDCA-3, and (e, f) BDCA-4 as described in the Patients and
methods section. Staining was detected by DAB (brown) and
nuclei counterstained by haematoxylin (blue). Few BDCA-1þ and
BDCA-3þ myeloid DCs were found in normal kidney, whereas a slight
and focal increase in the number of these immature cell populations
was observed in interstitial nephritis biopsies. The BDCA-4þ
DCs were hardly detectable both in normal and in pathological
tissue samples. Original magnifications were either (a, e, f)  200
or (b, c, d)  400. (g) Quantification of BDCA-1, BDCA-3, and
BDCA-4 cells in normal kidney and native kidney with interstitial
nephritis. Results are expressed as the mean7s.d. *Po0.05 versus
normal kidney.
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Figure 8 | Immunofluorescence staining of DCs in I/R pig model.
Identification of immature DC in frozen pig renal tissue during I-R.
The SWC3a expression, a specific cell surface marker, was analyzed by
confocal microscopy using a mouse anti-pig SWC3a monoclonal Ab
(green). TO-PRO-3 (blue) was used to stain nuclei. Original
magnification  630. (a) In basal conditions (T0), renal tissue showed
that SWC3a protein was barely detectable, (b) whereas few SWC3aþ
tubular and interstitial cells were observed 15 min after ischemia.
(c, d) After 15–30 min (T15, T30) of reperfusion, the number of
SWC3aþcells significantly increased and reached the peak with a
diffuse tubulo-interstitial distribution. (e) Quantification of SWC3a
expression level during I/R. Results are expressed as mean7s.d. of
SWC3aþ cells. *Po0.05 versus T0.
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DGF biopsies. In light of these findings, we investigated the
comparison of the myeloid/plasmacytoid DCs ratio before
and after transplantation in transplant recipients with DGF.
The myeloid/plasmacytoid DC ratio significantly increased in
DGF biopsies when compared with normal and pre-
transplant kidneys.
Our data would clearly suggest that the selective infiltra-
tion of myeloid DCs into the grafts of transplant recipients
with DGF may represent the link between the activation of
innate immunity featuring the ischemia-reperfusion injury
and the priming of the adaptive immune response, under-
lying acute graft rejection. Kim et al.26 already demonstrated
in a rat model of ischemia-reperfusion injury the activation
of the innate immune response as shown by the dramatic
increase in the kidney expression of toll-like receptors and
their specific ligands and the subsequent infiltration of DCs.
Interestingly, they reported that these changes were already
present in the first day and peaked after 5 days from the
induction of ischemia-reperfusion.26 These data are in
accordance with both our experimental pig model where
we demonstrated myeloid DC infiltration already after
15 min of reperfusion, and with our clinical observation.
Indeed, our patients with DGF underwent graft biopsy within
10 days from transplantation. However, Kim et al.26 did not
characterize DC sub-population. In addition, they also
observed a significant upregulation of class II major
histocompatibility complex antigen on infiltrating DCs,
suggesting their maturation. In our human model, we did
not observe any increase in DC-LAMP-positive cells, clearly
demonstrating that infiltrating DCs were immature.
The model used by Kim et al.,26 however, was based on
ischemia-reperfusion of native kidneys. An experimental
model closer to our human condition was the one used by
Penfield et al.7 These authors reported a significant interstitial
DC infiltration in a model of kidney transplantation from
Brown Norway donors into F1 Lewis/Brown Norway
recipients.7 The F1 recipients were tolerant to the parental
Brown Norway antigens and, thus, any graft damage
observed could be only due to injury occurring during
transplantation surgery.7 Also in this model, DC infiltration
peaked at 7 days after transplantation and therefore, after the
potential exposure to ischemia-reperfusion. However, also in
this model, the DCs were mostly mature, expressing class II
major histocompatibility complex, but the authors did not
perform any further characterization of the infiltrating DCs.
Some information on the effect of transplantation on DC
sub-population are now available in human kidney trans-
plant recipients, although these data are only related to
circulating DC and to patients with immediate recovery of
graft function. Hesselink et al.27 reported the kinetics of
myeloid and plasmacytoid DCs in peripheral blood of 24
kidney allograft recipients before and after transplantation,
and in 23 donors before and after kidney donation. Surgery
resulted in a strong decline in the number of myeloid and
plasmacytoid DCs, both in kidney donors and in their
recipients.27 However, in donors, this effect was transient, as
the numbers of both DC subsets had normalized completely
by the third postoperative month. In contrast, the recovery of
myeloid DC counts in kidney transplant recipients was only
incomplete at the end of the 3-month follow-up, despite
tapering of immunosuppression.26 The same pattern of
circulating DC sub-population in the immediate post-
transplant period was independently confirmed by Womer
et al.28 Both these observations indirectly suggest that
myeloid DCs may be recruited at the graft level. The
reduction in circulating myeloid DC, indeed, may be linked
to an increased recruitment of these cells within the graft and
with the subsequent priming of adaptative immune response.
This hypothesis is indirectly confirmed by the observation
that the number of circulating myeloid DC is inversely
correlated with the degree of graft rejection in heart
transplant.29 Interestingly, this correlation was not present
with plasmacytoid DCs.29 Our study confirms directly the
hypothesis that in the post-transplantation period, there is a
significant trafficking of myeloid, but not plasmacytoid DC
within the graft. It is conceivable that this impaired
plasmacytoid DC recruitment at the tubulointerstitial level
is further emphasized in the presence of the ischemia-
reperfusion injury underlying DGF. We could not compare
graft biopsies from transplant recipients with DGF and those
from patients with immediately functioning graft for ethical
reasons. However, as a post-transplant control group, we
used graft biopsies of patients with tubular damage due to
CNI nephrotoxicity. This control group allowed us to exclude
that myeloid DCs infiltration was due either to transplanta-
tion per se or to acute tubular necrosis, although we cannot
exclude that the differences we observed could be time-
related, as the control and the study groups underwent graft
biopsy at a slightly different time after transplantation. In
addition, our animal model of ischemia-reperfusion injury
would further confirm the ability of tissue reperfusion, even
after short-term ischemia, to induce the infiltration of
myeloid DCs within minutes from the release of renal artery
clamp. The pathophysiological consequence of this altered
myeloid/plasmacytoid DC ratio within the transplanted
kidney may be an altered balance between tolerance and
rejection of the graft. It is well known that tolerance can be
obtained through a central or peripheral action.30 Central
tolerance is established in the thymus by clonal deletion of
potentially self-reactive T cells. In addition, Treg cells help to
maintain peripheral tolerance by actively suppressing the
activation and population expansion of self-reactive T cells.
In several transplantation models, Treg cells have been shown
to be important in the induction and maintenance of
tolerance to foreign molecules.31–33 Ochando et al.18 per-
formed fully allogeneic vascularized cardiac transplants and
subjected recipient mice to a well characterized tolerogenic
protocol that is dependent on Treg cell development.34,35 In
this context, they identified plasmacytoid DCs as alloantigen-
presenting cells that mediate tolerance to vascularized
allografts. Alloantigen-presenting plasmacytoid DCs acquired
and processed cell-derived transplantation antigens and, after
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tolerogenic treatment, migrated ‘preferentially’ to lymph
nodes, where they induced antigen-specific Treg cell develop-
ment. These data provide direct evidence that plasmacytoid
DCs can act as ‘professional’ tolerance-inducing alloantigen-
presenting cells in vivo.
Thus, our observation would suggest that ischemia-
reperfusion injury underlying DGF may cause an unbalance
between intragraft myeloid and plasmacytoid DC potentially
linking this event with acute graft rejection. However, larger
studies are warranted to further establish this link, as the
number of patients included in this study does not allow to
draw any definitive conclusion on the clinical consequences
of our observation.
PATIENTS AND METHODS
Patients
Twenty-one primary kidney transplant recipients from
cadaveric donors were enrolled in this observational study.
We excluded, from the study, all patients with a pre-
transplant panel reactive antibodies (Abs) 40%, present or
historical evidence of neoplasia, active systemic infection,
biopsy-proven acute rejection. All patients included in the
study received 500 mg of methylprednisolone intra-opera-
tively, followed by 250 mg of prednisone daily, with the dose
tapered to 25 mg by day 8 and 5 mg by day 60; 20 mg of a
chimeric monoclonal anti-CD25 Ab (Simulect, Novartis,
Basel, Switzerland) intravenously on days 0 and 4, mycophe-
nolate mofetil (Cell-Cept, Roche, Basel, Switzerland) 1 g bid,
cyclosporine (Neoral, Novartis) at a dose of 5 mg/kg/day
aiming at C2 levels between 800 and 1000 ng/ml.
The presence of DGF was defined as the need for dialysis
in the first week after transplantation. According to these
criteria, in our study population, 15 patients presented a
DGF and six patients presented an immediately functioning
graft (post-transplant control group). The main demographic
and clinical features of the patients included in the study are
summarized in Table 1.
According with our clinical practice, all kidneys before
transplantation underwent a wedge biopsy. In all patients
with DGF, we performed a second graft biopsy 7–15 days after
transplantation, according to our standard clinical protocol.
A portion of this diagnostic biopsy was used for this study.
The patients of the post-transplant control group underwent
renal biopsy within 6 months from transplantation for a
rapid deterioration of graft function. All patients with DGF
presented acute tubular necrosis with no evidence of acute
rejection (including peritubular capillary deposition of C4d)
and/or acute CNI nephrotoxiciy. The biopsies of the post-
transplant control group were characterized by acute tubular
necrosis due to CNI nephrotoxicity. A portion of each
collected renal biopsy specimen was immediately snap-frozen
in a cryostat-embedding medium (OCT, Bio-Optica, Milan,
Italy) and stored in liquid nitrogen.
As negative control, we used apparently normal tissue
fragments from kidneys of six subjects who underwent renal
biopsy for persistent microhematuria. As positive control, we
used biopsies of transplanted kidneys of six patients with
acute rejection. As a further control group, we included
biopsies of native kidneys from four patients with acute drug-
induced interstitial nephritis.
We included in the study only those patients with a graft
biopsy core with an adequate sampling according to the Banff
consensus conference (at least 10 glomeruli and two arterial
sections).36 The analysis was limited to the cortical region of
each graft biopsy.
The study was approved by the local ethics committee.
Renal ischemia-reperfusion injury model
Small Landrace pigs (three female and three male) weighting
12–18 kg were used. The animals were allowed to become
accustomed to their surroundings for at least 5 days before
surgery. All operative procedures were performed under
general anesthesia (azaperone 2 mg/kg and atropine 0.04 mg/
kg), and the animals were cared for our standard protocol.
The study was approved by the local ethical committee. The
left renal vascular pedicle was atraumatically isolated by
laparoscopy and a vessel loop was positioned around the
renal artery with a right angle clamp. A renal biopsy was
performed before ischemia. After 15 min, a second fragment
of renal tissue was obtained and thereafter the vessel loop was
released. Multiple biopsies were then performed 15 and
30 min after reperfusion. A portion of each biopsy specimen
was immediately snap-frozen in OCT (Bio-Optica) medium
and stored in liquid nitrogen, whereas another portion was
fixed in buffered formalin (4%) for 12 h and embedded in
paraffin using standard procedures.
Antibodies
The primary monoclonal Abs used in this study recognize
BDCA-1, BDCA-3, and BDCA-4, as markers of myeloid and
plasmacytoid DCs (Mylteni Biotech, Bologna, Italy); DC-
LAMP, as a specific marker of mature DCs (Immunotech,
Marseilles, France); and SWC3a, as a specific marker of swine
DCs (BD Biosciences Pharmingen, San Diego, CA, USA). All
Table 1 | Main demographic and clinical features of the
patients included in the study
DGF CNI nephrotoxicity
Patients (n) 15 6
Age (years) 55.2712.6 42.3710.3
Donor age (years) 47.1710.2 29.6712.4*
Donor cause of death (trauma) 4/15 3/6
Donor creatinine clearance (ml/min) 63.0723.1 89.3718.6*
Donor hypertension 6/15 0/6*
Cold ischemia time (hours) 18.875.1 11.272.9*
Mismatches (n) 3.271.1 3.371.2
Length of DGF (days) 13.274.3 0
Acute rejection episodes (within
the first year after transplantation)
0 0
Creatinine clearance (ml/min)
1 year after transplantation 75.8726.5 81.0717.7
Abbreviations: CNI, calcineurin inhibitor; DGF, delayed graft function.
*Po0.05 vs DGF.
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Abs were purified by chromatography and tested on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis.
The mouse monoclonal anti-CD1c (BDCA-1) (isotype
IgG2a) Ab recognizes the epitope 1A of the BDCA-1 antigen
expressed on a major sub-population of human myeloid DCs
(about 0.3% of blood leukocytes).21 CD1c (BDCA-1)þ
myeloid DCs have been designated as type-1 myeloid DCs
(MDC1s).
The mouse monoclonal anti-CD141 (BDCA-3) (isotype
IgG1) Ab recognizes the epitope 3B of the BDCA-3 antigen
expressed at high levels on a minor sub-population of human
myeloid DCs (about 0.02% of blood leukocytes).19,21 CD141
(BDCA-3)þ CD1c (BDCA-1)– myeloid DCs have been
designated type-2 myeloid DCs (MDC2s). The mouse
monoclonal anti-CD304 (BDCA-4) (isotype IgG1) Ab
recognizes the epitope 4A of the BDCA-4 antigen specifically
expressed on human circulating plasmacytoid DCs.19,20
Unlike CD303 (BDCA-2), expression of CD304 (BDCA-4)
is upregulated on plasmacytoid DCs and induced on myeloid
DCs upon culturing.20 As a marker of mature DC, we used an
Ab raised against DC-LAMP (clone 104.G4). The DC-LAMP
antigen (70–90 kDa) is a new member of the LAMP family.22
DC-LAMP is specifically expressed by mature DCs located in
T-cell areas of lymphoid tissues, which are known as
interdigitating DCs.
The 74-22-15A (SWC3a) Ab, an isotype class-switch
variant of monoclonal Ab 74-22-15, reacts with a 230-kDa
protein expressed by DCs.23,24 This clone was clustered as
anti-SWC3a at the Swine CD workshop.25
Tissue Immunofluorescence and Confocal Laser Scanning
Microscopy
The expressions of BDCA-1, BDCA-3, BDCA-4, DC-LAMP,
and SWC3a were evaluated on frozen human and pig kidney
sections (6mm-thick and fixed in acetone) by indirect
immunofluorescence and confocal microscopy.
The fixed sections were washed in phosphate-buffered
saline pH 7.4 and then incubated: (1) for 45 min in blocking
buffer (phosphate-buffered saline pH 7.4, 5% Goat Serum
(Sigma, Milan, Italy)) at room temperature in a dark and
humidified container, (2) overnight at 41C in primary Ab
diluted in blocking buffer (the anti-BDCA-1and anti-BDCA-3
Abs diluted 1:20, the anti-BDCA-4 and anti-DC-LAMP Abs
diluted 1:100), and (3) for 2 h with the appropriate secondary
Abs (Alexa Fluor 488 goat anti-mouse IgG, diluted 1:400,
Molecular Probes, Eugene, OR, USA) at room temperature.
The sections were washed in phosphate-buffered saline after
each step, counterstained with TO-PRO-3 (Molecular
Probes), mounted in GEL/MOUNT (Biomeda Corp., Foster
City, CA, USA) and finally sealed with nail varnish. Negative
controls of the immunostaining technique were prepared by
omitting the primary Abs. The sections were viewed under
the Leica TCS SP2 (Leica, Wetzlar, Germany) confocal laser-
scanning microscope using  40 and  63 objective lenses.
The number of BDCA-1þ , BDCA-3þ , BDCA-4þ , DC-
LAMPþ, and SWC3aþ cells was measured in at least 10 high
power ( 630) fields/section by two independent observers
blinded to the origin of the slides. The final counts were the
mean of the two measures. In no case, we observed an inter-
observer variability higher than 20%.
Immunohistochemical analysis of BDCA-1þ , BDCA-3þ , and
BDCA-4þcells in renal graft with DGF
For immunohistochemistry, acetone-fixed cryosections
(6 mm) were prepared and incubated with specific mouse
monoclonal Abs against BDCA-1, BDCA-3, and BDCA-4
(1:5, Mylteni Biotech) for 1 h at 371C, after blocking
endogenous peroxidase activity with 0.3% H2O2. The tissue
samples were then incubated with Dako Real EnVision
Detection System/HRP, according to the manufacturer’s
instructions (Dako, Glostrup, Denmark). The reaction was
visualized by Dako Real Diaminobenzidine (DAB) tetrahy-
dro-chloride Chromogen solution, giving a brown precipi-
tate. The sections were washed in phosphate-buffered saline
after each step, counterstained with Mayers haematoxylin
(blue) and mounted with glycerol (DakoCytomation, Car-
pintera, CA, USA). Negative controls were obtained employ-
ing a non-immune mouse monoclonal IgG (IgG1 isotype) as
primary Ab. Staining was evaluated by optical light micro-
scopy using a Leika microscope fitted with a Coolpix 990
digital camera (Nikon, Calenzano, Italy).
Statistical Analysis
Data are expressed as the mean7standard deviation (s.d.).
Difference between groups were analyzed by one-way analysis
of variance or paired t-test analysis, as appropriate. A P-value
o0.05 was considered statistically significant.
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